19th August 2026
As biopharma manufacturers face unprecedented demand, the therapies they are developing have also become increasingly advanced. Cell and gene therapies are no longer experimental treatments, but their rise as mainstream medical interventions has put an added sense of pressure on the industry to scale up production without sacrificing precision and quality. This has laid the foundations for something of a technological revolution in bioproduction, spurred on by a convergence of production challenges and clinical promise.
But how can the industry, and the biologics sector in particular, meet the demands of this new pharmaceutical landscape?


